Skip to main content
TipRanks
Go Ultimate75% OFF

Riken Vitamin Co., Ltd. (4526) AI Stock Analysis

0 Followers
JP:4526

Riken Vitamin Co., Ltd.

(TSE/TYO:4526)

Select Model
Rating:75Outperform
Price Target:JPY 4,118.00â–²(12.51% Upside)
Action:upgraded
Date:08/17/26

Riken Vitamin offers a strong valuation profile and robust technical momentum, underscored by a pristine, low-debt balance sheet. However, the score is weighed down by operational headwinds, specifically margin compression and deteriorating free cash flow, which remain significant fundamental risks.

Positive Factors
Conservative Balance SheetDebt-to-equity of about 0.09 and equity of roughly ¥83.3B give Riken Vitamin a substantial cushion against financial stress. This conservative capitalization preserves flexibility to fund operations, invest in its food businesses, and withstand softer earnings.
Negative Factors
Weakening Cash ConversionFree cash flow fell sharply while conversion of net income declined to about 16%, from 40% in 2025 and 71% in 2024. This weakens internally generated funding, may reflect higher reinvestment or working-capital needs, and reduces cash durability.

Riken Vitamin Co., Ltd. (4526) vs. iShares MSCI Japan ETF (EWJ)

-10%0%10%20%30%40%JP:4526+32.48%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 104.54B
Dividend Yield
3.01%
Average Volume (3M)
95.44K
Price to Earnings (P/E)
15.2
Beta (1Y)
0.26
Revenue Growth
3.68%
EPS Growth
-25.50%
Country
Japan
Employees
1,887
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

Riken Vitamin Co., Ltd. Business Overview & Revenue Model

Company Description

Riken Vitamin Co., Ltd., based in Tokyo, Japan, operates across several key sectors: food ingredients, food applications, healthcare, and chemicals. The company provides a diverse portfolio of food additives, including emulsifiers used in a wide arra...

Riken Vitamin Co., Ltd. Financial Statement Overview

Summary

A pristine balance sheet with extremely low debt and growing equity partially mitigates the negative impact of contracting margins, declining net income, and severely weakened cash flow generation.

Income Statement

60Neutral

Balance Sheet

90Very Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue98.18B96.30B95.58B91.48B88.75B79.23B
Gross Profit30.14B29.77B31.27B29.89B27.24B25.57B
EBITDA11.90B11.58B16.04B15.35B11.71B24.23B
Net Income7.08B7.04B9.39B8.76B6.41B21.58B
Balance Sheet
Total Assets117.34B116.39B113.00B118.78B105.22B102.66B
Cash, Cash Equivalents and Short-Term Investments17.91B20.07B22.30B23.38B19.16B17.30B
Total Debt7.40B7.14B9.98B16.09B14.60B17.57B
Total Liabilities32.94B33.01B33.80B42.13B33.85B36.12B
Stockholders Equity84.36B83.34B79.16B76.61B71.34B66.52B
Cash Flow
Free Cash Flow0925.00M3.12B7.42B5.67B3.44B
Operating Cash Flow05.96B7.89B10.45B7.83B6.82B
Investing Cash Flow01.75B353.00M-554.00M-2.03B-3.66B
Financing Cash Flow0-8.04B-9.96B-7.08B-4.58B-7.57B

Riken Vitamin Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price3660.00

Price Trends

50DMA3296.98Positive
100DMA3209.16Positive
200DMA3035.91Positive

Market Momentum

MACD118.47Negative
RSI64.86Neutral
STOCH68.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4526, the sentiment is Positive. The current price of 3660.00 is above the 20-day moving average (MA) of 3429.25, above the 50-day MA of 3296.98, and above the 200-day MA of 3035.91, indicating a bullish trend. The MACD of 118.47 indicates Negative momentum. The RSI at 64.86 is Neutral, neither overbought nor oversold. The STOCH value of 68.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4526.

Riken Vitamin Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

JP:4526 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:2264JP:226477OutperformJPY 403.95B18.64―2.06%2.67%112.23%
JP:4526JP:452675OutperformJPY 83.46B15.18―3.01%3.68%-25.50%
JP:3139JP:313966NeutralJPY 35.14B9.92―4.22%5.61%-15.32%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
JP:2802JP:280262NeutralJPY 3.96T25.9420.53%1.16%9.89%126.77%
JP:2927JP:292751NeutralJPY 12.01B10.22―4.72%5.11%-19.41%
JP:2607JP:260749NeutralJPY 367.49B24.36―1.33%3.57%54.54%

* Consumer Defensive Sector Average

Performance Comparison

0%20%40%60%JP:4526JP:2802JP:2264JP:2607JP:2927JP:3139Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4526 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4526Riken Vitamin Co., Ltd.3660.00900.2832.62%
JP:2802Ajinomoto Co 4227.00464.0312.33%
JP:2264Morinaga Milk Industry Co., Ltd.1251.50341.2737.49%
JP:2607Fuji Oil Holdings, Inc.4275.00812.3923.46%
JP:2927AFC-HD AMS Life Science Co., Ltd.848.0028.633.49%
JP:3139Lacto Japan Co., Ltd.3510.0039.181.13%

Riken Vitamin Co., Ltd. Corporate Events

Riken Vitamin Announces Progressive Dividend Policy, Higher Forecast

Nov 12, 2026

Riken Vitamin Co., Ltd. announced that its board had resolved to change the company’s dividend policy and increase its dividend forecast. The new policy, applying from the fiscal year ending March 31, 2027, calls for progressive dividends and a minim...

Riken Vitamin Revises Medium-Term Management Plan 2027

Nov 12, 2026

Riken Vitamin’s board resolved to revise its Medium-Term Management Plan 2027 after overseas operations recorded an operating loss in fiscal 2025 amid a Chinese economic downturn and intensified commodity-price competition in Southeast Asia and Europ...

Riken Vitamin Reports Higher Six-Month Sales and Lower Operating Profit

Nov 12, 2026

Riken Vitamin Co., Ltd. is listed on the Tokyo Stock Exchange under stock code 4526; the release covers its consolidated results for the six months ended September 30, 2026. The company reported net sales of 50,189 million yen, up 6.2% year over year...

Riken Vitamin Maintains Stable Payout With 55 Yen Interim Dividend

Oct 27, 2026

Riken Vitamin Co., Ltd. has resolved to pay an interim dividend of 55 yen per share for the fiscal year ending March 2027, with a record date of September 30, 2026 and payment scheduled for December 7, 2026. The interim payout, sourced from retained...

Riken Vitamin Nears Share Buyback Ceiling with Tokyo Market Purchases

Sep 24, 2026

Riken Vitamin Co., Ltd. has completed a share buyback program under a Board-approved mandate, acquiring 111,700 of its own common shares via market purchases on the Tokyo Stock Exchange between September 1 and September 18, 2026. The latest tranche c...

Riken Vitamin Advances Share Buyback, Acquires Over Half of Authorized Amount

Sep 1, 2026

Riken Vitamin Co., Ltd. has disclosed the latest progress in its share buyback program, reporting the purchase of 164,300 common shares for approximately 536 million yen on the Tokyo Stock Exchange between August 1 and August 31, 2026. This move is p...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026